Lindsay rosenwald

As one of the most productive contributors to the field of biotechnology, Dr. Lindsay Rosenwald’s impact is centered around his Paramount Group of Companies, of which he is the Founder and Chairman. These organizations span a wide spectrum, from Paramount Corporate Development, a company that facilitates and coordinates drug advancement and corporate development activities for Paramount’s group of portfolio companies, to Paramount BioSciences, a multi-national pharmaceutical development and healthcare investment firm focusing on the conception, cultivation, and financial backing of new biotechnology companies. Additionally, supporting Paramount and its many portfolio companies is Paramount BioCapital, a registered broker-dealer with FINRA, which raises capital and support for Paramount’s portfolio companies. To date, Paramount BioCapital has raised nearly $950 million for these companies since its launch in 1991.
Dr. Rosenwald graduated from Abington High School, located in southeast Pennsylvania, in 1973, and went on to graduate from Pennsylvania State University with a major in Finance in 1977, graduating Beta Gamma Sigma. After then attending Temple University at their School of Medicine, he interned at Abington Medical Hospital while engaged in private practice. In 1986 his attention turned to Wall Street, where the unique combination of the disciplines of medicine and finance, a specialization that few enjoyed at the time, set him on the path to the massive impact he has had today.
Paramount BioCapital was founded in 1991 and has since then transformed the fields of bioresearch and biotechnology. Ongoing accomplishments around this time include abiraterone acetate, a drug that was being developed by his company Cougar Biotechnology. Cougar was researching this drug’s usage in the treatment of prostate cancer, and was not yet in Phase III clinical trials when Johnson & Johnson purchased Cougar for approximately $1,000,000,000. Also notable is Arsenic Trioxide, a drug developed by one of Dr. Rosenwald’s portfolio companies, which at the time held the record for the drug to move most rapidly from development to FDA approval. Not content to stop with personal accomplishments or direct benefit to his companies and his portfolio companies, Dr. Lindsay Rosenwald also founded the Rosenwald Foundation, a nonprofit fund which has donated millions of dollars to support numerous scientific and medical educational establishments. These funds and grants assist the innovative scientists of today in research and development, shaping the progression of biotechnology into tomorrow.
With his nearly 20-year background in the fields of biotechnology, pharmaceuticals, biomedicine, and finance, Dr. Rosenwald is truly placed as the vanguard of cutting-edge research and development. The unique combination of disciplines he studied - finance and medicine - have positioned him in the rare and unique perspective to identify opportunities to expand the frontiers of high-tech medicine and finance those pioneers that work on the forefront of the field. With his rich and varied history in a remarkably specialized industry, Dr. Lindsay Rosenwald’s prolific accomplishments are matched by few in the industry.

Main Menu

See Also

Main Menu